Europe’s medical devices industry top deal activity in May 2021
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here

Europe’s medical devices industry saw a drop of 24.24% in deal activity during May 2021

22 Jun 2021

Europe’s medical devices industry saw a drop of 24.24% in deal activity during May 2021, when compared with the last 12-month average, led by Murano Bidco’s $1.36bn acquisition of Vectura Group, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the image source into your website to display the chart.


A total of 25 medical devices industry deals worth $2.6bn were announced for the region in May 2021, against the 12-month average of 33 deals.

Of all the deal types, venture financing saw most activity in May 2021 with 13 transactions, representing a 52% share for the region.

In second place was M&A with seven deals, followed by private equity deals with five transactions, respectively capturing a 28% and 20% share of the overall deal activity for the month.

In terms of value of deals, M&A was the leading category in Europe’s medical devices industry with $1.91bn, while private equity and venture financing deals totalled $383.58m and $292.02m, respectively.

Europe medical devices industry deals in May 2021: Top deals

The top five medical devices deals accounted for 89.4% of the overall value during May 2021.

The combined value of the top five medical devices deals stood at $2.31bn, against the overall value of $2.6bn recorded for the month.

The top five medical devices industry deals of May 2021 tracked by GlobalData were:

1) Murano Bidco’s $1.36bn acquisition of Vectura Group

2) The $390m acquisition deal with Inivata by NeoGenomics

3) IP Group, M&G Investments, Nikon, Temasek Holdings (Private) and Wellington ManagementLLP’s $280.17m private equity deal with Oxford Nanopore Technologies

4) The $155m acquisition of Immunodiagnostic Systems by PerkinElmer

5) HAT SGR, Hitachi Ventures, Leaps by Bayer, Samsung NEXT Fund, Sony Innovation Fund and Unilever Ventures’ venture financing of Huma Therapeutics for $130m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.